NASDAQ: CGEM
Cullinan Therapeutics Inc Stock Ownership - Who owns Cullinan Therapeutics?

Insider buying vs selling

Have Cullinan Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Jennifer MichaelsonCSci2026-09-084,000$4.30
$17.20kBuy
Jennifer MichaelsonCSci2026-09-088,000$21.57
$172.56kSell
Jennifer MichaelsonCSci2026-08-1330,000$4.30
$129.00kBuy
Jennifer MichaelsonCSci2026-08-1330,000$20.26
$607.80kSell
Jennifer MichaelsonChief Scientific Officer2026-07-064,000$4.30
$17.20kBuy
Jennifer MichaelsonChief Scientific Officer2026-07-068,000$17.82
$142.56kSell
Mary Kay FentonChief Financial Officer2026-06-301,541$8.60
$13.25kBuy
Jacquelyn L. SumerChief Legal Officer2026-06-302,470$8.60
$21.24kBuy
Jennifer MichaelsonChief Scientific Officer2026-05-057,800$14.60
$113.88kSell
Jennifer MichaelsonChief Scientific Officer2026-05-054,000$4.30
$17.20kBuy

1 of 4

CGEM insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when CGEM insiders and whales buy or sell their stock.

CGEM Shareholders

What type of owners hold Cullinan Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Ansbert Gadicke25.11%16,157,644$241.23MInsider
Lynx1 Capital Management LP13.93%8,963,500$133.83MInsider
Ubs Oncology Impact Fund LP11.88%7,648,268$114.19MInsider
Morana Jovanembiricos7.20%4,631,022$69.14MInsider
Vision Scs F26.96%4,476,350$66.83MInsider
F2 Bioscience I 2017 Ltd6.89%4,430,964$66.15MInsider
Owen Hughes0.79%506,226$7.56MInsider
Patrick Baeuerle0.65%417,434$6.23MInsider
Nadim Ahmed0.61%390,803$5.83MInsider
Corrine Savill0.37%240,990$3.60MInsider

1 of 3

CGEM vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
CGEM0.11%76.11%Net SellingNet Selling
MLTX0.09%22.01%Net Selling
ORIC0.12%20.85%Net SellingNet Selling
ODTX0.07%25.83%Net Buying
SVRA0.09%99.91%Net SellingNet Selling

Cullinan Therapeutics Stock Ownership FAQ

Who owns Cullinan Therapeutics?

Cullinan Therapeutics (NASDAQ: CGEM) is owned by 0.11% institutional shareholders, 76.11% Cullinan Therapeutics insiders, and 23.78% retail investors. Ansbert Gadicke is the largest individual Cullinan Therapeutics shareholder, owning 16.16M shares representing 25.11% of the company. Ansbert Gadicke's Cullinan Therapeutics shares are currently valued at $254.48M.

If you're new to stock investing, here's how to buy Cullinan Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.